Action Maia Biotechnology - MAIA

Maia Biotechnology Inc (MAIA) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

1,41

( 4,44% )

Prix Achat

Prix Vente

Volume échangé

379 895

1,35 Fourchette du Jour 1,41

0,87 Plage de 52 semaines 3,19

Cap du marché

85,729M

Clôture Veille

1,35

Ouverture

1,35

Dernière Transaction

112858

1.41

Dernière heure de transaction

00:30:00

Volume financier

US$ 521 430

VWAP

1,3726

Volume moyen (3 m)

US$ 791 911

Actions en circulation

60 800 758

Rendement du Dividende (LTM)

Ratio Cours sur Bénéfices

-2,11

Bénéfice par action (BPA)

-0,66

Chiffre d'affairess (LTM)

Bénéfice net (LTM)

-24,25M

MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Ce... MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois. Show more

Secteur

Healthcare

Industrie

Biotechnology & Life Sciences

Site Web

maiabiotech.com

Siège social

Chicago, United States

Fondé

2026

Maia Biotechnology Inc est coté dans le secteur Healthcare de la American Stock Exchange avec le ticker MAIA. Le dernier cours de clôture d'Maia Biotechnology était de US$1,35. Au cours de la dernière année, les actions de Maia Biotechnology ont été négociées dans une fourchette de prix de US$ 0,87 à US$ 3,19.

Maia Biotechnology compte actuellement 60 800 758 actions en circulation. La capitalisation boursière d'Maia Biotechnology est de US$85,73 million. Maia Biotechnology a un ratio cours/bénéfice (ratio PE) de -2.11.

MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer

Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June 25, 2026 (GLOBE...

MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University

Georgia’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recognized at the...

MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial

Additional data from MAIA’s THIO-101 expansion may further support an accelerated approval filing with the FDA...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0.05	3.67647058824	1.36	1.48	1.32	479149	1.38367846	CS
4	0.1	7.63358778626	1.31	1.56	1.25	1055820	1.37848775	CS
12	0.11	8.46153846154	1.3	1.56	1.16	752020	1.34162273	CS
26	-0.08	-5.36912751678	1.49	3.19	1.16	898218	1.67124161	CS
52	-0.25	-15.0602409639	1.66	3.19	0.87	737692	1.61567052	CS
156	-0.79	-35.9090909091	2.2	5.99	0.82	419601	1.87245851	CS
260	-2.69	-65.6097560976	4.1	9.64	0.82	364321	2.31144081	CS

MAIA - Frequently Asked Questions (FAQ)

What is the current Maia Biotechnology Inc share price?

The current share price of Maia Biotechnology Inc is US$ 1,41

How many Maia Biotechnology Inc shares are in issue?

Maia Biotechnology Inc has 60 800 758 shares in issue

What is the market cap of Maia Biotechnology Inc?

The market capitalisation of Maia Biotechnology Inc is USD 85,73M

What is the 1 year trading range for Maia Biotechnology Inc share price?

Maia Biotechnology Inc has traded in the range of US$ 0,87 to US$ 3,19 during the past year

What is the PE ratio of Maia Biotechnology Inc?

The price to earnings ratio of Maia Biotechnology Inc is -2,11

What is the registered address of Maia Biotechnology Inc?

The registered address for Maia Biotechnology Inc is 444 West Lake Street, Chicago, Illinois, 60606

What is the Maia Biotechnology Inc website address?

The website address for Maia Biotechnology Inc is maiabiotech.com

Which industry sector does Maia Biotechnology Inc operate in?

Maia Biotechnology Inc operates in the Biotechnology & Life Sciences sector

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Maia Biotechnology Inc (MAIA)

Maia Biotechnology Inc (MAIA) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Maia Biotechnology Inc

MAIA Dernières nouvelles

MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer

MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University

MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial

MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial

MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion

MAIA Biotechnology Announces Open Market Purchases by CEO and Director

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer

MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University

MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial

MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial

MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion

MAIA Biotechnology Announces Open Market Purchases by CEO and Director

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

MAIA - Frequently Asked Questions (FAQ)

MAIA Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités